HER2, HER3, and TROP2: Diagnostic Testing and Treatment Implications in Breast, GI, and Lung Cancers

Review the latest expert guidance on assessing and targeting HER2, HER3, and TROP2 in the metastatic setting for diverse malignancies with on-demand Webcasts and downloadable slides from CCO’s live Webinars, along with expert-authored commentaries, a pocket guide on best practices for testing, and brief Medical Minute slide/audio presentations for oncologists and pathologists.
Mark D. Pegram, MD
Program Director
Axel Grothey Headshot
Axel Grothey, MD
Mark D. Pegram, MD
Michael F. Press, MD, PhD

Downloadable Slidesets

Download this short summary slideset of key takeaway points from a live presentation on HER2 testing and how this can inform treatment in metastatic breast cancer.

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Released: July 30, 2020

Download this short summary slideset of key takeaway points from a live presentation on approved and emerging investigational HER2-, HER3-, and TROP2-targeted therapies for metastatic breast cancer.

Mark D. Pegram, MD
Program Director
Released: August 24, 2020

Download this short summary slideset of key takeaway points from a live presentation on HER2 testing and targeted therapy in advanced gastrointestinal cancers.

Axel Grothey Headshot Axel Grothey, MD Michael F. Press, MD, PhD Released: September 30, 2020

Download this short summary slideset of key takeaway points from a live presentation on HER2, HER3, and TROP2 testing and targeted therapy in advanced breast and gastrointestinal cancers.

Axel Grothey Headshot Axel Grothey, MD Mark D. Pegram, MD Michael F. Press, MD, PhD Released: October 30, 2020

Download this slideset for expert perspectives on key nuances of HER2 testing in metastatic breast cancer and how test results inform HER2-targeted therapy decisions.

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Released: July 30, 2020

Download this slideset to review key data and expert perspectives on approved and emerging investigational HER2-, HER3-, and TROP2-targeted therapies for metastatic breast cancer.

Mark D. Pegram, MD
Program Director
Released: August 21, 2020

Download this slideset to review key data and expert perspectives on HER2 testing and targeted therapy in advanced gastrointestinal cancers.

Axel Grothey Headshot Axel Grothey, MD Michael F. Press, MD, PhD Released: September 25, 2020

Download this slideset for an expert overview of HER2 testing in metastatic breast and GI cancers and the use novel HER2, HER3, and TROP2-targeted therapeutics for these malignancies.

Mark D. Pegram, MD
Program Director
Axel Grothey Headshot Axel Grothey, MD Michael F. Press, MD, PhD
Released: October 29, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue